石杉碱甲联合来士普对血管性痴呆患者的疗效观察  

Clinical Observation on Effects of Combination of Huperzine A and Escitalopram in Treating Vascular Dementia

作　　者：肖迎春[1] 刘楠[1] 周宜灿[1] 陈荣华[1] 

机构地区：[1]福建医科大学附属协和医院,福州350001

出　　处：《光明中医》2013年第3期580-582,共3页GUANGMING JOURNAL OF CHINESE MEDICINE

摘　　要：目的评价石杉碱甲联合来士普治疗血管性痴呆的疗效及安全性。方法选择108例血管性痴呆患者,随机分为3组,每组36例。各组均给予相同的基础药物治疗。此外,A组(石杉碱甲治疗组)予石杉碱甲100mg,bid口服;B组(来士普治疗组)予来士普10mg,qd口服;C组(石杉碱甲联合来士普治疗组)予石杉碱甲100mg,bid加用来士普10mg,qd口服,疗程均为12周。治疗前及治疗后分别做简易精神状态量表(MMSE)、日常生活自理量表(ADL)及神经电生理P300等检测,评价其疗效,并进行安全性评价。结果治疗12周后,各治疗组认知、行为能力均有改善,P300潜伏期均有缩短(P<0.05),说明石杉碱甲与来士普对血管性痴呆均有治疗作用。其中石杉碱甲联合来士普组与单独使用石杉碱甲或来士普组相比改善更明显,差异有显著性(P<0.05);不良反应少见且轻微。结论石杉碱甲联合来士普治疗血管性痴呆有较好的疗效及安全性。Objective To study the clinical effects and safety of Huperzine A and Escitalopram in treatment of vascular dementia （ Va D）. Methods 108 patients with Va D were randomly divided into Huperzine A therapy group, Escitalopram therapy group and combination of Huperzine A and Escitalopram therapy group （each had 36 patients）. Patients in each groups were given general drugs, and patients in Huperzine A therapy group were treated with Huperzine A （0.2g/d） , patients in Escitalopram therapy group were treated with Escitalopram （lOmg/d） ,,the group treated with Huperzine A and Escitalopram were treated with Huperzine A （0. 2g/d）and Escitalopram （10mg/d）. Before and 12 weeks after treatment, the mini mental status examination （MMSE） , activity of daily living （ ADL, using Barthel Index） and P300 potentials were measured by the same doctor. Results After 12 weeks of treatment, The cognitive function and behavioral abilities were improved in each group, and the effect of latency shorten and amplitude elevate of P300 potentials in each group, specially in the group treated with Huperzine A and Escitalopram. Conclusion Combination of Huperzine A and Escitalopram can markedly ameliorate the cognitive function and behavioral abilities in patients of Va D, and was well tolerated and safe.

关 键 词：石杉碱甲 来士普 血管性痴呆 治疗 

分 类 号：R749.1[医药卫生—神经病学与精神病学]